FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 319 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Five Questions With…Keon. June 16, 2022 EMA Recommends Granting a Marketing Authorisation for Tarlatamab April 17, 2026 5 ways cancer can impact sexual wellbeing May 17, 2023 FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 Load more HOT NEWS For Older Adults, Geriatric Assessment Reduces Cancer Treatment Side Effects Nivolumab: Μία σημαντική θεραπευτική επιλογή Commemorating and Making History: The National Cancer Act 50th Anniversary Could A Form of Cell Death Enhance Cancer Immunotherapy?
